Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market

Executive Summary

Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients

You may also be interested in...



FDA Approves Zyprexa IM; Milestone In Lilly GMP Turnaround

Lilly's Zyprexa IM has cleared FDA three years after a pre-approval inspection for the intramuscular antipsychotic triggered a period of Good Manufacturing Practices compliance issues for the company

FDA Approves Zyprexa IM; Milestone In Lilly GMP Turnaround

Lilly's Zyprexa IM has cleared FDA three years after a pre-approval inspection for the intramuscular antipsychotic triggered a period of Good Manufacturing Practices compliance issues for the company

Pfizer/Pharmacia Merger: Tidbits From The SEC Filings

COX-2 co-marketing amendment: Pfizer would gain majority control over Pfizer/Pharmacia COX-2 co-marketing executive committee should Pharmacia terminate the merger agreement under certain conditions, Pfizer's Aug. 14 S-4 merger filing with the Securities & Exchange Commission states. Pfizer would name three members to the five-person committee should Pharmacia end the deal; Pfizer is currently represented by two members. The company would also be able to appoint a chairperson to "any or all" of the six subcommittees of the executive committee under the amended agreement. The merger breakup fee is $1.6 bil...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040091

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel